Diamyd Medical has treated half of the patients in European registration study

Diamyd Medical reported today that 166 out of a total of 320 patients, who are part of the European Phase III study of the Diamyd® diabetes vaccine, have now been included in the study. Discussions with regulatory agencies are ongoing regarding how the brisk rate of recruitment in Europe can best be utilized in Diamyd’s global Phase III program. The company estimates that the program will be fully recruited during 2009.The global Phase III program includes two studies with respectively 320 patients in Europe and 320 in the United States ages 10 to 20. The objective of the program is to